ClinicalTrials.gg
Not yet recruitingNCT07338890REAL-SMARTUpdated Jan 14, 2026

Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease

An observational study in Superficial Femoral Artery Stenosis, Iliac Artery Stenosis and Popliteal Artery Stenosis, sponsored by Cordis US Corp.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Cordis US Corp. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Constriction, Pathologic with a site in Spain — 1 open to participants now, 4 under way, none of them phase 3. Constriction, Pathologic · Spain.

Started
2026
the only one that year
Observational
7 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Cordis US Corp.

Among the 13 studies in Constriction, Pathologic with a site in Spain, this one is the only one that started in 2026, is one of 7 observational ones, and was the 13th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

1 of the 13 studies in Constriction, Pathologic with a site in Spain is open now.

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Constriction, Pathologic with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long-term safety and performance per the intended use of the S.M.A.R.T.™ Nitinol Stent System (SMART 120/150), S.M.A.R.T.™ CONTROL™ Nitinol Stent System (SMART CONTROL) and S.M.A.R.T.™ Flex Vascular Stent System (SMART Flex) in the treatment of iliac and femoropopliteal artery disease.

Read the detailed description

The REAL-SMART study is a multi-center, non-randomized, observational analysis of retrospective data collected on all subjects treated with SMART 120/150, SMART CONTROL or SMART Flex. The purpose of this study is to evaluate long-term safety and performance per the intended use of the three (3) study devices. Each device constitutes a separate study arm and each arm is further stratified by indication, of which there are two per device. The study is conducted in approximately 20 sites located in approximately three (3) European countries with high volume use of one or more of the study devices. The enrollment and data collection take approximately 6-8 months.

03

Conditions studied

  • Superficial Femoral Artery Stenosis
  • Iliac Artery Stenosis
  • Popliteal Artery Stenosis

Keywords

  • Superficial Femoral Artery Stenosis
  • Iliac Artery Stenosis
  • Popliteal Artery Stenosis
  • SMART CONTROL Nitinol Stent System
  • SMART FLEX Vascular Stent System
  • SMART Nitinol Stent System
  • SFA Stenosis
  • PPA Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects to be included in this study are those treated with SMART 120/150, SMART CONTROL or SMART Flex, according to the respective Instructions for Use, for stenosis in the iliac, superficial femoral and/or proximal popliteal arteries. Approximately 20 sites located in approximately three (3) European countries with high volume use of one or more of the study products will participate.

Eligibility criteria

Inclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to include in the study:

  • Subjects treated with SMART 120/150, SMART CONTROL or SMART Flex according to the respective Instructions for Use for treatment in the iliac, superficial femoral and/or proximal popliteal arteries.
  • If an EC-approved waiver is not obtained, then documented informed consent from the subject or legal representative granting permission to share the subject's clinical data It is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment/procedure or until time of death, whichever came first.

It is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment/procedure or until time of death, whichever came first. Subjects not included because follow-up information is unavailable will be documented, wherever possible, with respect to demographics and presenting disease state to determine whether they are similar to subjects with follow-up that are enrolled.

Exclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to exclude in the study:

  • Women who were pregnant or lactating at the time of the procedure.
  • Pediatric subjects (\<18 years of age) at the time of the procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects with stenotic lesions of the superficial femoral artery (SFA) treated with SMART 120/150.

    The Cordis S.M.A.R.T.TM Nitinol Stent System (SMART 120/150) is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery (SFA).

    Device: S.M.A.R.T.™ Nitinol Stent System (SMART 120/150)

  • Subjects with stenotic lesions of the proximal popliteal artery (PPA) treated with SMART 120/150.

    The Cordis S.M.A.R.T.TM Nitinol Stent System (SMART 120/150) is indicated in enabling treatment in patients with atherosclerotic disease of the proximal popliteal artery (PPA).

    Device: S.M.A.R.T.™ Nitinol Stent System (SMART 120/150)

  • Subjects with stenotic lesions of the iliac artery treated with SMART CONTROL.

    The Cordis S.M.A.R.T.TM CONTROLTM Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the iliac artery.

    Device: S.M.A.R.T.™ CONTROL ™ Nitinol Stent System

  • Subjects with stenotic lesions of the superficial femoral artery (SFA) treated with SMART CONTROL.

    The Cordis S.M.A.R.T.TM CONTROLTM Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery (SFA).

    Device: S.M.A.R.T.™ CONTROL ™ Nitinol Stent System

  • Subjects with stenotic lesions of the superficial femoral artery (SFA) treated with SMART Flex.

    The Cordis S.M.A.R.T.TM Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the superficial femoral artery (SFA).

    Device: S.M.A.R.T.™ Flex Vascular Stent System

  • Subjects with stenotic lesions of the proximal popliteal artery (PPA) treated with SMART Flex.

    The Cordis S.M.A.R.T.TM Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the proximal popliteal artery (PPA).

    Device: S.M.A.R.T.™ Flex Vascular Stent System

Interventions

  • DeviceS.M.A.R.T.™ Nitinol Stent System (SMART 120/150)

    The Cordis S.M.A.R.T.™ Nitinol Stent System is intended to deliver a self-expanding endovascular stent to the peripheral vasculature via a sheathed delivery system. The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T. ™ Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery and proximal popliteal artery.

  • DeviceS.M.A.R.T.™ CONTROL ™ Nitinol Stent System

    The Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System is intended to deliver a self-expanding endovascular stent to the iliac and/or superficial femoral arteries via a sheathed delivery system. The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T. ™ CONTROL™ Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of iliac and/or superficial femoral arteries.

  • DeviceS.M.A.R.T.™ Flex Vascular Stent System

    The Cordis S.M.A.R.T.™ Flex Stent is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the superficial femoral artery (SFA). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T.™ Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the superficial femoral artery and proximal popliteal artery.

06

What researchers measure

Primary outcomes

  1. Technical success of SMART 120/150 in patients with obstructive SFA disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  2. Major amputation in patients treated with SMART 120/150 for obstructive SFA disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  3. Technical success of SMART 120/150 in patients with obstructive PPA disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  4. Major amputation in patients treated with SMART 120/150 for obstructive PPA disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  5. Technical success of SMART CONTROL in patients with obstructive iliac artery disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  6. Major amputation in patients with SMART CONTROL for obstructive iliac artery disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  7. Technical success of SMART CONTROL in patients with obstructive SFA disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  8. Major amputation in patients treated with SMART CONTROL for obstructive SFA disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  9. Technical success of SMART Flex in patients with obstructive SFA disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  10. Major amputation in patients treated with SMART Flex for obstructive SFA disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  11. Technical success of SMART Flex in patients with obstructive PPA disease

    Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure

    Time frame: At the conclusion of the index procedure

  12. Major amputation in patients treated with SMART Flex for obstructive PPA disease

    Major amputation at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

Secondary outcomes

  1. Patency at 12 months post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  2. Patency at 12 months post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  3. Patency at 12 months post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  4. Patency at 12 months post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  5. Patency at 12 months post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  6. Patency at 12 months post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis

    Time frame: At 12 months post-index procedure

  7. Target lesion restenosis in patients treated with SMART 120/150 for obstructive SFA disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  8. Target lesion restenosis in patients treated with SMART 120/150 for obstructive PPA disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  9. Target lesion restenosis in patients treated with SMART CONTROL for obstructive iliac artery disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  10. Target lesion restenosis in patients treated with SMART CONTROL for obstructive SFA disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  11. Target lesion restenosis in patients treated with SMART Flex for obstructive SFA disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  12. Target lesion restenosis in patients treated with SMART Flex for obstructive PPA disease

    Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  13. Procedural success in patients treated with SMART 120/150 for obstructive SFA disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  14. Procedural success in patients treated with SMART 120/150 for obstructive PPA disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  15. Procedural success in patients treated with SMART CONTROL for obstructive iliac artery disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  16. Procedural success in patients treated with SMART CONTROL for obstructive SFA disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  17. Procedural success in patients treated with SMART Flex for obstructive SFA disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  18. Procedural success in patients treated with SMART Flex for obstructive PPA disease

    Procedural success, defined as successful stent deployment without occurrence of any procedural complications

    Time frame: At the conclusion of the index procedure

  19. Target Lesion Revascularization in patients treated with SMART 120/150 for obstructive SFA disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  20. Target Lesion Revascularization in patients treated with SMART 120/150 for obstructive PPA disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  21. Target Lesion Revascularization in patients treated with SMART CONTROL for obstructive iliac artery disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  22. Target Lesion Revascularization in patients treated with SMART CONTROL for obstructive SFA disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  23. Target Lesion Revascularization in patients treated with SMART Flex for obstructive SFA disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  24. Target Lesion Revascularization in patients treated with SMART Flex for obstructive PPA disease

    Target Lesion Revascularization through 12 months post-index procedure

    Time frame: Through 12 months post-index procedure

  25. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  26. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  27. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  28. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  29. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  30. All-Cause Mortality through 30 days post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    All-Cause Mortality through 30 days post-index procedure

    Time frame: Through 30 days post-index procedure

  31. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  32. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  33. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  34. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  35. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  36. Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  37. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  38. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  39. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  40. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  41. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  42. Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  43. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  44. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  45. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  46. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  47. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  48. Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure

    Time frame: Through 36 months (3 years) post-index procedure

  49. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  50. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  51. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  52. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  53. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  54. Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure

    Time frame: Through 60 months (5 years) post-index procedure

  55. Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  56. Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  57. Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  58. Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  59. Rate of stent fractures at 6 months by type post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  60. Rate of stent fractures at 6 months by type post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of stent fractures at 6 months post-index procedure

    Time frame: At 6 months post-index procedure

  61. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  62. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  63. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  64. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  65. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART Flex for obstructive SFA disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

  66. Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART Flex for obstructive PPA disease

    Rate of stent fractures at 12 months post-index procedure

    Time frame: At 12 months post-index procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for May 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2026
First posted
Jan 14, 2026
StartEst.
Jan 31, 2026
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338890
Lead sponsor
Cordis US Corp.
Collaborators
Rede Optimus Hospitalar SA
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jan 31, 2026 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

Kwame Ofori
Contact
kwame.ofori@cordis.com
832-407-3326
Rajesh Nathan
Contact
rajesh.nathan@cordis.com
Nusrath Sultana
study director · Cordis US Corp.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion